Publication & Citation Trends
Publications
12 total
A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors.
Cited by 0
Semantic Scholar
Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301
Cited by 0
Semantic Scholar
Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial.
Cited by 1
Semantic Scholar
Infigratinib versus placebo in patients with resected urothelial cancer (UC) bearing FGFR3 mutation or fusion: Primary DFS analysis from the phase 3, randomized PROOF302 study.
Cited by 4
Semantic Scholar
PROOF 301: Results of an early discontinued randomized phase 3 trial of the oral FGFR inhibitor infigratinib vs. gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma (CCA) with an FGFR2 gene fusion/rearrangement.
Cited by 10
Semantic Scholar
Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: A phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC).
Cited by 13
Semantic Scholar
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
Cited by 391
OpenAlex
Clinical Response of Cefiderocol Compared with Imipenem/Cilastatin in the Treatment of Adults with Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis: Results from a Multicenter, Double-blind, Randomized Study (APEKS-cUTI) PDF
Cited by 26
OpenAlex
Research Topics
Antibiotics Pharmacokinetics and Efficacy
(6)
Prostate Cancer Treatment and Research
(5)
Antibiotic Resistance in Bacteria
(3)
Pneumonia and Respiratory Infections
(2)
Estrogen and related hormone effects
(2)
Affiliations
Bayer (United States)
Shionogi (United States)
BridgeBio (United States)
Myovant Sciences (United States)